OrganaBio, a hub for tissue sourcing, cell isolation, cryopreservation, contract manufacturing services and clinical sample processing, has expanded its flagship Cell Processing and Cryopreservation (CPC) Services hub in Irvine, California to support clinical trial services for a large-cap pharmaceutical company. The expansion comes a year after opening the Irvine lab and just months after the October launch of OrganaBio’s CPC Services division.
 
The Irvine facility already services 7 major clinical trial cities in the region, offering services like peripheral blood mononuclear cell (PBMC) isolation and cryopreservation, as well as storage, logistics, and batch shipping on request.
 
As its pharmaceutical partner looked to add a new site in the region for an existing clinical trial, CPC Services quickly and simply duplicated activities performed at its Miami-based location. The rapid expansion was enabled by OrganaBio’s electronic Quality Management System that enables unified training, tech transfer and SOPs, as well as equipment and operator qualifications.
 
“Through CPC Services, we’ve developed a quick and flexible approach to bicoastal trial expansion,” said Priya Baraniak, Ph.D., Chief Business Officer of OrganaBio. “In the last two years working with two multinational large-cap pharmaceutical companies, as well as other trial sponsors, we have developed an unparalleled reputation for quality. This includes a 99.9% success rate handling 2,000 samples, processing them in half the time required and leading the industry with 99.1% PBMC viability.”
 
Expanded CPC Services are already operational at the Irvine facility, and able to support trials at sites in Los Angeles, San Diego, Las Vegas, Phoenix, Tucson, San Jose, San Francisco, and more.  In addition to the Miami and Irvine sites, CPC Services will soon expand to locations in Chicago, Nashville, Ann Arbor and Atlanta, enabling high-quality and fast trial support across the U.S.